Long‐term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first‐line chemotherapy

S. Kunito,S. Takakura,Chie Nagata,M. Saito,N. Yanaihara,Kyosuke Yamada,A. Okamoto,H. Sasaki,K. Ochiai,Tadao Tanaka
DOI: https://doi.org/10.1111/j.1447-0756.2012.01884.x
2012-12-01
Abstract:Aim:  Several previous reports showed that irinotecan hydrochloride plus cisplatin (CPT‐P) was a candidate first‐line chemotherapy regimen for clear cell adenocarcinoma of the ovary (CCC). However, long‐term survival in CCC patients treated with CPT‐P as first‐line chemotherapy remains to be determined. The aim of the present study was to evaluate the long‐term results of CPT‐P as first‐line chemotherapy for CCC.
What problem does this paper attempt to address?